Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension
- 1 October 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 44 (7) , 1488-1496
- https://doi.org/10.1016/j.jacc.2004.06.060
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Beraprost therapy for pulmonary arterial hypertensionJournal of the American College of Cardiology, 2003
- Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated AnalysesJournal of Urology, 2002
- VardenafilExpert Opinion on Investigational Drugs, 2002
- Inhaled Iloprost for Severe Pulmonary HypertensionNew England Journal of Medicine, 2002
- Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial HypertensionCirculation, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- IC351 (tadalafil, Cialis): update on clinical experienceInternational Journal Of Impotence Research, 2002
- Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: Response to iloprost inhalationJournal of the American College of Cardiology, 2001
- GENERAL CARDIOLOGY: Pulmonary arterial hypertension: new ideas and perspectivesHeart, 2001
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996